Cardiovascular Disease Specialty

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women

A coronary artery calcium score of zero was the strongest negative risk marker for ruling out future cardiovascular disease events over 10 years, resulting in a mean 46% relative reduction in pre-test

Effect: improvement; DLR 0.54 (SD 0.12) for CVD; DLR 0.49 (0.10) in men, 0.59 (0.12) in women